BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35548968)

  • 1. EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE.
    Holotiuk IS; Kryzhanivska AY; Holotiuk SI; Maliborska SV; Holotiuk VV
    Exp Oncol; 2022 May; 44(1):75-82. PubMed ID: 35548968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES.
    Holotiuk IS; Kryzhanivska AY; Holotiuk SI; Holotiuk VV; Maliborska SV
    Exp Oncol; 2022 Dec; 44(4):300-306. PubMed ID: 36811539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
    Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
    Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
    Werida RH; Elshafiey RA; Ghoneim A; Elzawawy S; Mostafa TM
    Support Care Cancer; 2022 Sep; 30(9):7281-7292. PubMed ID: 35596774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial.
    Ghoreishi Z; Esfahani A; Djazayeri A; Djalali M; Golestan B; Ayromlou H; Hashemzade S; Asghari Jafarabadi M; Montazeri V; Keshavarz SA; Darabi M
    BMC Cancer; 2012 Aug; 12():355. PubMed ID: 22894640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
    Ghoreishi Z; Keshavarz S; Asghari Jafarabadi M; Fathifar Z; Goodman KA; Esfahani A
    BMC Cancer; 2018 Oct; 18(1):958. PubMed ID: 30290775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors.
    Kober KM; Olshen A; Conley YP; Schumacher M; Topp K; Smoot B; Mazor M; Chesney M; Hammer M; Paul SM; Levine JD; Miaskowski C
    Mol Pain; 2018; 14():1744806918816462. PubMed ID: 30426838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.
    Hiramoto S; Asano H; Miyamoto T; Takegami M; Kawabata A
    PLoS One; 2021; 16(12):e0261473. PubMed ID: 34972132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study.
    Miyamoto T; Hiramoto S; Kanto A; Tsubota M; Fujitani M; Fukuyama H; Hatanaka S; Sekiguchi F; Koizumi Y; Kawabata A
    J Pharmacol Sci; 2021 May; 146(1):49-57. PubMed ID: 33858655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin-aldosterone system inhibitors are associated with improved paclitaxel-induced peripheral neuropathy in lung cancer: a study using administrative claims data.
    Ihara Y; Sawa K; Imai T; Kimura T; Otani M; Kawai R; Takatori S; Shintani A
    Support Care Cancer; 2023 Nov; 31(12):730. PubMed ID: 38019339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
    Tanabe Y; Hashimoto K; Shimizu C; Hirakawa A; Harano K; Yunokawa M; Yonemori K; Katsumata N; Tamura K; Ando M; Kinoshita T; Fujiwara Y
    Int J Clin Oncol; 2013 Feb; 18(1):132-8. PubMed ID: 22105895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive effects of self-administered cryotherapy on paclitaxel-induced peripheral neuropathy in patients with early-stage breast cancer: a propensity score analysis.
    Shimanuki Y; Hashimoto H; Kawazoe H; Uozumi R; Udagawa R; Watabe D; Nakamura T; Yamaguchi M; Terakado H
    Pharmazie; 2021 Jun; 76(6):261-265. PubMed ID: 34078520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.
    Li L; Li J; Zuo Y; Dang D; Frost JA; Yang Q
    J Pain; 2019 May; 20(5):528-539. PubMed ID: 30471428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation.
    Argyriou AA; Chroni E; Koutras A; Iconomou G; Papapetropoulos S; Polychronopoulos P; Kalofonos HP
    J Pain Symptom Manage; 2006 Sep; 32(3):237-44. PubMed ID: 16939848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors.
    Kober KM; Mazor M; Abrams G; Olshen A; Conley YP; Hammer M; Schumacher M; Chesney M; Smoot B; Mastick J; Paul SM; Levine JD; Miaskowski C
    J Pain Symptom Manage; 2018 Dec; 56(6):908-919.e3. PubMed ID: 30172061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
    Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
    Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy.
    Kawashiri T; Inoue M; Mori K; Kobayashi D; Mine K; Ushio S; Kudamatsu H; Uchida M; Egashira N; Shimazoe T
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
    Kanbayashi Y; Hosokawa T; Kitawaki J; Taguchi T
    Anticancer Res; 2013 Mar; 33(3):1153-6. PubMed ID: 23482795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cilostazol on preventing paclitaxel-induced neuropathy in patients with breast cancer: A randomized controlled trial.
    Haroun EA; Mansour NO; Eltantawy A; Shams MEE
    Pharmacotherapy; 2023 Sep; 43(9):872-882. PubMed ID: 37199288
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Abdelfattah NM; Solayman MH; Elnahass Y; Sabri NA
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):471-477. PubMed ID: 34280009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.